Center for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya.
Centers for Disease Control and Prevention, Nairobi, Kenya.
J Infect Dis. 2022 Jun 15;225(12):2097-2105. doi: 10.1093/infdis/jiaa490.
Respiratory syncytial virus (RSV) is an important cause of respiratory illness worldwide; however, burden data on mother-infant pairs remain sparse in sub-Saharan Africa, where human immunodeficiency virus (HIV) is prevalent. We evaluated the impact of maternal HIV infection on the burden of RSV among mothers and their infants in western Kenya.
We enrolled pregnant women (≤20 weeks' gestation) and followed them and their newborns weekly for up to 3-6 months postpartum, to document cases of acute respiratory illness (ARI). Nasal/oropharyngeal swabs were collected and tested for RSV using polymerase chain reaction. Analyses were stratified by maternal HIV status and incidence was computed per 1000 person-months.
Compared to RSV-negative ARI cases, RSV-positive cases were associated with cough, apnea, and hospitalization among infants. RSV incidence per 1000 person-months among mothers was 4.0 (95% confidence interval [CI], 3.2-4.4), and was twice that among the HIV-infected mothers (8.4 [95% CI, 5.7-12.0]) compared to the HIV-uninfected mothers (3.1 [95% CI, 2.3-4.0]). Among infants, incidence per 1000 person-months was 15.4 (95% CI, 12.5-18.8); incidence did not differ by HIV exposure or prematurity.
HIV infection may increase the risk of RSV illness among pregnant women. Future maternal RSV vaccines may have added benefit in areas with high HIV prevalence.
呼吸道合胞病毒(RSV)是全球范围内导致呼吸道疾病的重要原因;然而,在艾滋病毒(HIV)流行的撒哈拉以南非洲,母婴对 RSV 负担的数据仍然很少。我们评估了母婴 HIV 感染对肯尼亚西部母婴 RSV 负担的影响。
我们招募了孕妇(≤20 周妊娠),并在产后 3-6 个月内每周对她们及其新生儿进行随访,以记录急性呼吸道疾病(ARI)病例。采集鼻/咽拭子,采用聚合酶链反应检测 RSV。分析按产妇 HIV 状况分层,每 1000 人月计算发病率。
与 RSV 阴性 ARI 病例相比,RSV 阳性病例与婴儿咳嗽、呼吸暂停和住院有关。母亲每 1000 人月 RSV 发病率为 4.0(95%置信区间 [CI],3.2-4.4),与 HIV 阴性母亲(3.1 [95% CI,2.3-4.0])相比,HIV 感染母亲(8.4 [95% CI,5.7-12.0])的发病率是其两倍。婴儿每 1000 人月的发病率为 15.4(95% CI,12.5-18.8);发病率与 HIV 暴露或早产无关。
HIV 感染可能会增加孕妇患 RSV 疾病的风险。未来针对 RSV 的母体疫苗可能在 HIV 流行率高的地区具有额外的益处。